Estradiol Gel, 0.1% recall — Ani Pharmaceuticals, Inc. (Class II)

Ani Pharmaceuticals, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Estradiol Gel, 0.1% — a Class II recall, initiated 2026-05-12 and posted to the FDA enforcement report on 2026-05-27, under recall number D-0543-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Defective Container; packets were found to be either empty or partially full.”. From the product description, the form is gel, the strengths given are 0.1%, 0.25 mg and 0.25 g, the package is described as 30 packets per carton and it is marked Rx only. 1 National Drug Code number is printed in the record: 70954-531-20. Distribution is recorded as “Nationwide in the USA” — Nationwide (US), with the recalling firm on record in MN, United States. It is the only recall number the FDA has filed under event ID 98947. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0543-2026
FDA event ID 98947
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Ani Pharmaceuticals, Inc.
Recall initiated 2026-05-12
Reported by FDA 2026-05-27
Report lag 15 days from initiation to report
Distribution Nationwide in the USA — Nationwide (US)
Firm location on record MN, United States
Product description (source) Estradiol Gel, 0.1%, 0.25 mg, 0.25 g per packet, 30 packets per carton, Rx only, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623. NDC 70954-531-20

Reason reported by FDA

Defective Container; packets were found to be either empty or partially full.

12 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

8 identifying values matched by exact pattern in the 25-word product description above; each is a literal substring of it.

Product named Estradiol Gel
Form Gel
Strength 0.1% · 0.25 mg · 0.25 g
Package 30 packets per carton
NDC 70954-531-20
Marketing category Rx only
Distributed by ANI Pharmaceuticals, Inc.

Other indexed recalls from Ani Pharmaceuticals, Inc.

2 indexed records name Ani Pharmaceuticals, Inc. as the recalling firm, across 2 FDA events, reported 2026-05-27 to 2026-07-01. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mLD-0619-2026Class III10 mg/5 mL · Oral Solution2026-07-01

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Atomoxetine Capsules HCL, 10 mgD-0538-2026Safecor Health, LLCClass II2026-05-27
Liraglutide Injection, 18 mg/3 mLD-0541-2026Lupin Pharmaceuticals Inc.Class II2026-05-27
Gas-X, 125 mgD-0542-2026Haleon US Holdings LLCClass II2026-05-27
Erythromycin Tablets, 250 mgD-0544-2026Zydus Pharmaceuticals (usa) IncClass II2026-05-27
Erythromycin Tablets, 500 mgD-0545-2026Zydus Pharmaceuticals (usa) IncClass II2026-05-27
cimzia (certolizumab pegol)D-0546-2026Ucb Biosciences Inc.Class II2026-05-27
fentaNYL Citrate, 2,2500 mcg/50mLD-0548-2026Integradose Compounding Services LLCClass II2026-05-27
Vitamin B-Complex, 799 mcg/5mLD-0549-2026Safecor Health, LLCClass II2026-05-27

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 7 nearest to 2026-05-27 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Oasis Tears PF, 10mLD-0525-2026Oasis Medical, Inc.10mL · Eye Drops2026-05-20
Buprenorphine Hydrochloride, 0.3mg/mLD-0527-2026Endo Usa, Inc.0.3mg/mL · Injection2026-05-20
Ascend Laboratories, 25 mgD-0547-2026Ascend Laboratories, LLC25 mg · Extended-Release Tablets2026-05-20
DELFLEX, 1.5%D-0512-2026Fresenius Medical Care Holdings, Inc.1.5% · Solution2026-05-13
DELFLEX, 2.5%D-0513-2026Fresenius Medical Care Holdings, Inc.2.5% · Solution2026-05-13
Duloxetine Delayed-Release Capsules, 30 mgD-0514-2026Ajanta Pharma Ltd.30 mg · Delayed-Release Capsules2026-05-13
Duloxetine Delayed-Release Capsules, 60 mgD-0515-2026Ajanta Pharma Ltd.60 mg · Delayed-Release Capsules2026-05-13

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 70954-531-20 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Ani Pharmaceuticals, Inc. (2 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0543-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0543-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-27
Ingested
2026-08-22
Record hash
41327e412cc4e3da

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.